National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Trelegy™ Ellipta™ which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.

 

NCPE Assessment Process Complete
Rapid review commissioned 30/04/2018
Rapid review completed 18/06/2018
Rapid Review outcome A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.